Lucarelli M, Palitti F, Carotti D, Cianfriglia M, Signoretti C, Bozzi A, Strom R
Department of Human Biopathology, University of Rome La Sapienza, Italy.
FEBS Lett. 1996 Nov 4;396(2-3):323-6. doi: 10.1016/0014-5793(96)01124-6.
Genome-wide DNA hypermethylation induced by 3'-azido-3'-deoxythymidine (AZT) has been suggested to be involved in the development of AZT resistance. We used a CD4 T-lymphoblastoid CEM line and its AZT-resistant MT500 variant with reduced thymidine kinase activity. Evaluation of total DNA methylation, after AZT treatment, failed to show an increase in the 5-methylcytosine level in both parental and AZT-resistant cells. The effect was instead observed at a more specific gene level, on the three HpaII sites present in exon 1 of the human thymidine kinase gene. These results suggest that AZT treatment can induce site-specific hypermethylation, even in the absence of a more general DNA hypermethylating effect.
有研究表明,3'-叠氮-3'-脱氧胸苷(AZT)诱导的全基因组DNA高甲基化与AZT耐药性的产生有关。我们使用了CD4 T淋巴母细胞样CEM细胞系及其胸苷激酶活性降低的AZT耐药MT500变体。AZT处理后对总DNA甲基化的评估未能显示亲代细胞和AZT耐药细胞中5-甲基胞嘧啶水平的增加。相反,在更特异的基因水平上观察到了这种效应,即在人胸苷激酶基因外显子1中存在的三个HpaII位点上。这些结果表明,即使在没有更普遍的DNA高甲基化效应的情况下,AZT处理也能诱导位点特异性高甲基化。